Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
Illumina, National Cancer Center Japan Collaborate on Nasopharyngeal Cancer Study
The study will analyze blood samples of up to 96 patients using Illumina's TruSight Oncology 500 circulating tumor DNA comprehensive genomic profiling assay.
Stanford researchers said the cost of their approach is in line with Illumina sequencing but did not share data on error rate and other benchmarks at this time.
SomaLogic's Illumina Codevelopment Deal Suggests Future of Label-Based Proteomics Lies in NGS
Premium
The assay development deal was "necessary to remain competitive" for SomaLogic, according to MD Anderson proteomics researcher Philip Lorenzi.
Illumina Touts New Partnerships, Sequencing Technology at JP Morgan Healthcare Conference
The company's preliminary fourth quarter 2021 revenues grew 25 percent, year over year, while full-year revenues grew 39 percent.
Illumina, SomaLogic Ink Codevelopment Agreement for Proteomics Assays With Sequencing Readout
Illumina will endeavor to integrate SomaLogic's aptamer-based protein counting technology with its NGS and bioinformatics platforms by 2024.